| This week's sponsor is Premier Research. | |  | iRECIST: The Future of Solid Tumor Evaluation?
The iRECIST guidance on solid tumor response focuses new attention on standardizing and validating immune response criteria. Will it be the new standard for clinical trials? See what our experts think. Premier Research. It's what we do. Best. |
Featured Story | | | Tuesday, October 3, 2017 Intra-Cellular Therapies raised its target of $150 million from a new public offering that will help it prepare for an FDA filing for lead drug lumateperone in schizophrenia next year. |
|
|
| This week's sponsor is Deloitte. | |  | |
Top Stories Tuesday, October 3, 2017 Cullinan Oncology has raised $150 million to build a portfolio of cancer R&D programs. The idea is to manage the risks inherent in drug development by placing bets on eight to 10 early-stage assets and selling those that show promise in the clinic. Tuesday, October 3, 2017 Ablynx has moved quickly to capitalize on the boost to its prominence and prospects provided by recent phase 3 data. The Belgian biotech has joined the reopened path from Europe to Wall Street in pursuit of $150 million (€128 million) to support its commercialization and clinical trial activities. Thursday, September 28, 2017 Learn how one company sought support at multiple junctures—from manufacturing to biomarker evaluation to market access—to enable a faster and more effective launch of their new programmed death receptor-1 (PD-1)-blocking antibody. Tuesday, October 3, 2017 Celgene has secured an option on two preclinical assets in development at Nimbus Therapeutics. The deal gives Celgene a chance to move into the slipstreams of Bristol-Myers Squibb and Pfizer in the race to bring a TYK2 inhibitor to market. Tuesday, October 3, 2017 A body of evidence is building behind Takeda and Myovant’s hormonal therapy in uterine fibroids, with late-stage Japanese data reinforcing positive phase 2 results with the drug in the U.S. Monday, October 2, 2017 Scientists at New York University’s Perlmutter Cancer Center have discovered that two commonly mutated genes in lung cancer may make some tumor cells especially vulnerable to CB-839, an experimental drug from Calithera Biosciences. They believe their findings could lead to more precise patient targeting in the ongoing clinical trials—and not just in lung cancer. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Sponsored by: Veeva Systems The 2017 Unified Clinical Operations Survey finds that 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. | 
